Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2009 2010 2011 2012 2013 2014 TTM 2015E 2016E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p

FINANCIAL BRIEF: For the six months ended 30 June 2015, SkyePharma PLC revenues increased 12% to L38.6M. Net income totaled L9.1M vs. loss of L17.7M. Revenues reflect Revenue increase of 13% to L27M, Royalty Income - Business increase of 29% to L10.8M. Net Income reflects Loss on Extinguishment of bonds decrease from L25.1M (expense) to L0K, Interest decrease of 81% to L1M (expense), Costs related to bond repayment decrease from L400K (expense) to L0K. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Jun '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2015
31st Dec 2016

Price Target: 4.08
(+18.11% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
4 brokers Broker Consensus Trend
Broker Recommendations for SkyePharma
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 1 0 1

Named Brokers and Analysts
Stifel Nicolaus and Company, Incorporated Max Herrmann , Edison Investment Research Francesco Gregori , N+1 Singer Jens Lindqvist Sheena Berry , FinnCap Michal Cabadaj ,

Profile Summary

Skyepharma PLC (Skyepharma) is a specialty pharmaceutical company. The Company is engaged in the development and delivery of oral and inhalation pharmaceutical products. The Company's products pipeline includes four inhalation products, 10 oral products, one topical product and one injectable product. The Company's products include flutiform, Exparel, Paxil CR, Sular, Diclofenacratiopharm, Madopar DR and Coruno, among others. The Company's product flutiform is a multi-dose pressurized metered dose inhaler, utilizing SkyeDry technology, containing steroid (fluticasone) and a beta agonist (formoterol). flutiform is indicated for the treatment of asthma. Exparel is a bupivacaine injectable product indicated for post-surgical pain management. The Product utilizes Pacira Pharmaceuticals' DepoFoam technology. The Company has approximately 10 approved oral products that are sold in over 80 countries.

Directors: Peter Grant (CEO) 59, Andrew Derodra (CFO) 48, John Murphy (GCN) 61, Frank Condella (NEC) 61, John Biles (NED) 67, Jean-Charles Tschudin (NID) 72, Thomas Werner (NID) 59,

No. of Employees: 92 No. of Shareholders: n/a

Last Annual December 31st, 2014
Last Interim June 30th, 2015
Incorporated February 18, 1910
Shares in Issue 104,812,259
Free Float 103.0m (98.3%)

SKP Share Price Performance SKPQuote
-4.9  -1.4%
Traded 2:58pm · Minimum 15 min delayed · NMS: 1.000k

Latest SKP News Announcements (delayed)

Upcoming SKP Events

Recent ↓
Wednesday 16th September, 2015
SkyePharma PLC at EBD Group BioPharm America
Thursday 4th June, 2015
SkyePharma PLC at Jefferies Global Healthcare Conference
Tuesday 24th March, 2015
SkyePharma PLC at Biotechnology Industry Organization (BIO) Asia International Conference

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy SKP

Access SKP Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis